Author Interviews, Education, JAMA, Race/Ethnic Diversity, Social Issues, Yale / 15.07.2022

MedicalResearch.com Interview with: Mytien Nguyen, MS MD-PhD Program, Yale School of Medicine, New Haven, Connecticut MedicalResearch.com:  What is the background for this study?  Response: It is well-recognized that diversity in the medical workforce is critical to improve health care access and achieve equity for neglected communities. Despite increased efforts to recruit diverse medical trainees, there remains a large chasm between the racial/ethnic and socioeconomic composition of the patient population and that of the physician workforce. (more…)
Author Interviews, Dermatology, Infections / 15.07.2022

MedicalResearch.com Interview with: Dr Dilip Kachhawa, MD Department of Skin & Venereal Disease Dr Sampurnanand Medical College Jodhpur, Rajasthan, India MedicalResearch.com:  What are the main findings? Response: Molluscum Contagiosum (MC) is an infection caused by molluscipoxvirus. It is difficult to study since the virus only survives in human skin, and therefore there isn’t an animal or cell model to study potential treatments. Molluscum lesions appear as raised, domed shaped skin-colored lesions and can occur anywhere on the body but are most common on the face, neck, arms, legs, and abdomen. Sometimes there are few lesions, but clusters of several lesions can appear. Children are the most likely to get molluscum, and the virus is highly contagious, transmitted by direct contact with infected skin or contaminated objects, like towels, linens and toys. Scratching can cause autoinoculation which is when a person reinfects themself. MC is very common, impacting an estimated 6 million adults and mostly children in the US each year. In 2010, there was an estimated 122 million cases worldwide. It occurs primarily in humid and warm climates, and transmission via swimming pools and bathtubs may be possible. Therefore, molluscum is often called “water warts.” Many physicians may take a “watch and wait” approach since the virus may clear on its own. However, it can take months to up to 5 years for some to experience complete clearance, In the meantime, the person is still highly contagious and may spread the virus to others, particularly children. Lesions can be bothersome, causing itching and sometimes a secondary infection. There is also a psychosocial component. In a recent study, 1 in 10 children with molluscum experienced a major quality of life issue. Berdazimer Gel, 10.3% is a potential first-in-class topical controlled-nitric oxide releasing medication containing Berdazimer (sodium), a new chemical entity, and the active ingredient in berdazimer gel 10.3%. The mechanism of action of berdazimer in the treatment of molluscum is unknown, but in vitro lab studies show that the nitric oxide, released when berdazimer is combined with a hydrogel, may impede viral replication and perhaps help body’s natural immune response against molluscum. (more…)
Author Interviews, Health Care Systems, JAMA / 12.07.2022

MedicalResearch.com Interview with: Dr. Joanna JiangJoanna Jiang, PhD Agency for Healthcare Research and Quality Rockville, Maryland MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Over the last decade we have seen two trends occurring to rural hospitals – closures and mergers. A hospital in financial distress could likely face closure. But if the hospital affiliates with a multihospital system, it may have access to resources from the system that help shelter the hospital from closure. That is exactly what we found in this study. System affiliation was associated with a lower risk of closure for financially distressed hospitals. However, among hospitals that were financially stable, system affiliation was associated with a higher risk of closure. This is somewhat puzzling and needs further study to better understand the reason for closure. (more…)
Author Interviews, Environmental Risks, Hepatitis - Liver Disease, JAMA / 06.07.2022

MedicalResearch.com Interview with: Dania Valvi, MD MPH PhD Assistant Professor Department of Environmental Medicine and Public Health Co-Director, MS in Epidemiology Icahn School of Medicine at Mount Sinai Email: [email protected] MedicalResearch.com:  What is the background for this study?    Response: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in children in the U.S., Europe and other world regions, currently affecting 1 in every 10 children, and 1 in every 3 children with obesity in the U.S. The rate of pediatric NAFLD has more than doubled in recent decades following the epidemic rates also noted for childhood obesity. There is increasing interest in the role that environmental chemical exposures may play in NAFLD etiology, since several animal studies have shown that prenatal exposures to endocrine-disrupting chemicals (EDCs) cause liver injury and damage; but, until now, the potential effects of prenatal EDC mixture exposures in pediatric NAFLD had not been studied. (more…)
Author Interviews, Education, JAMA, Pharmaceutical Companies / 06.07.2022

MedicalResearch.com Interview with: SooYoung VanDeMark, MBS Geisinger Commonwealth School of Medicine Scranton, Pennsylvania MedicalResearch.com:  What is the background for this study?   Response: Health care providers utilize subscription-based, point-of-care databases such as DynaMed and UpToDate to provide clinical care guidance and remain current on the latest evidence-based findings. Both of these websites maintain this content through a cadre of physician contributors who write and edit articles for these sites. These physician contributors are required to self-report any conflicts of interest (COI) as outlined by the respective policies on each website. However, prior COI research into similarly self-regulated areas, such as medical and pharmacology textbooks, and clinical practice guidelines, has found both appreciable potential COI and inconsistencies between self-reported and industry mandated disclosures (1-3). This study (4) explored the accuracy of physician contributors to DynaMed and UpToDate by comparing their self-reported disclosure status with the financial remunerations they received from the healthcare industry (e.g., pharmaceutical companies) as reported to the U.S. Centers for Medicare and Medicaid Services’ Open Payments database. Physician contributors who reported “nothing to disclose” on their respective article topic but had an entry on Open Payments for having received money from industry, were classified as discordant and, thus, as having the potential for a COI. Additionally, total remuneration, gender, and payment category were investigated more in depth for each database. (more…)
Allergies, Author Interviews, JAMA, Pediatrics / 06.07.2022

MedicalResearch.com Interview with: Victoria Soriano PhD Research Assistant/Officer, Population Allergy University of Melbourne   MedicalResearch.com:  What is the background for this study?  Response: Peanut allergy is one of the most common childhood food allergies, and children rarely grow out of it. The only proven way to prevent peanut allergy is to give infants age-appropriate peanut products in the first year of life. We previously showed there was a dramatic increase in peanut introduction from 2007-11 to 2018-19, following changes to infant feeding guidelines. We wanted to know if earlier peanut introduction would reduce peanut allergy in the general population (in Melbourne, Australia). (more…)
Author Interviews, Infections, NIH / 30.06.2022

MedicalResearch.com Interview with: Nihal Altan-Bonnet, Ph.D. Chief of the Laboratory of Host-Pathogen Dynamics NHLBI  MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Enteric viruses such as norovirus, rotavirus and astrovirus are responsible for nearly 1.5 billion global infections per year resulting in gastrointestinal illnesses and sometimes leading to death in the very young, in the elderly and in the immunocompromised. These viruses have been thought to traditionally infect and replicate only in the intestines, then shed into feces and transmit to others via the oral-fecal route (e.g. through ingestion of fecal contaminated food items). Our findings reported in Nature, using animal models of norovirus, rotavirus and astrovirus infection, challenge this traditional view and reveal that these viruses can also replicate robustly in salivary glands, be shed into saliva in large quantities and transmit through saliva to other animals. In particular we also show infected infants can transmit these viruses to their mothers mammary glands via suckling and this leads to both an infection in their mothers mammary glands but also a rapid immune response by the mother resulting in a surge in her milk antibodies. These milk antibodies may play a role in fighting the infection in their infants .  (more…)
Author Interviews, Brigham & Women's - Harvard, Heart Disease, JAMA, Lung Cancer, Supplements, USPSTF / 30.06.2022

MedicalResearch.com Interview with: Michael J. Barry, M.D Director of the Informed Medical Decisions Program Health Decision Sciences Center Massachusetts General Hospital. Professor of medicine at Harvard Medical School Dr. Barry was appointed as Vice Chair of USPSTF in March 2021. He previously served as a member from January 2017 through December 2020.   MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: The Task Force looked at the use of vitamin and mineral supplementation specifically for the prevention of heart disease, stroke, and cancer. We found that there is not enough evidence to recommend for or against taking multivitamin supplements, nor the use of single or paired nutrient supplements, to prevent these conditions. However, we do know that you should not take vitamin E or beta-carotene for this purpose. (more…)
Author Interviews, Brigham & Women's - Harvard, COVID -19 Coronavirus / 23.06.2022

MedicalResearch.com Interview with: SCOTT DRYDEN-PETERSON, MD Assistant Professor, Medicine, Harvard Medical School Research Affiliate, Immunology and Infectious Diseases Harvard T.H. Chan School Of Public Health Associate Physician, Medicine, Infectious Diseases Brigham And Women's Hospital Research Associate, Botswana Harvard AIDS Institute MedicalResearch.com:  What is the background for this study?  Response: The combination of the antiviral medicine nirmatrelvir and ritonavir (Paxlovid) which boosts antiviral levels was found to reduce the need for hospitalization by nearly 90% among unvaccinated people. Whether nirmatrelvir plus ritonavir can also help vaccinated people was uncertain. (more…)
Author Interviews, Cancer Research, COVID -19 Coronavirus, Lung Cancer, Surgical Research / 21.06.2022

MedicalResearch.com Interview with: Emanuela Taioli, MD, PhD Director, Institute for Translational Epidemiology Professor, Population Health Science and Policy Professor, Thoracic Surgery Icahn School of Medicine at Mount Sinai New York, NY MedicalResearch.com:  What is the background for this study?  Response: NYC experienced a halt on all elective care from March 22 to June 8, 2020, provoking reduced cancer screening rates, and delayed cancer care and treatment. We wanted to quantify the effect of the “pause” on cancer stage at diagnosis using lung cancer as an example of a condition where early diagnosis can dramatically modify survival. (more…)
Author Interviews, Brigham & Women's - Harvard, Neurology, Parkinson's / 21.06.2022

MedicalResearch.com Interview with: Vikram Khurana, MD, PhD Chief of the Division of Movement Disorders Department of Neurology Brigham and Harvard Medical School Principal investigator, Ann Romney Center for Neurologic Diseases at the Brigham MedicalResearch.com:  What is the background for this study?   Response: Proteins abnormally accumulate in brain cells (neurons and glial cells) in all neurodegenerative diseases. In Parkinson’s disease and related disorders, the key protein that accumulates and aggregates is called “alpha-synuclein.” Presumably, when a protein like alpha-synuclein abnormally folds and aggregates, the abnormal form of the protein can become toxic to the neuron, eventually leading to cell death. Equally, the protein may no longer be able to carry out its normal function. This begs the question – what does alpha synuclein actually do? Most evidence to date points to alpha-synuclein being involved in the transport of other proteins and chemicals around the cell, by closely associating with vesicles that are small circular containers enclosed by fat (“lipid) membranes. But alpha-synuclein is not just found associated with these vesicle membrane. It is found away from the membrane and it’s been unclear what it does there. (more…)
Author Interviews, COVID -19 Coronavirus, Vaccine Studies / 15.06.2022

MedicalResearch.com Interview with: Hiam Souheil Chemaitelly Ph.D. Assistant Professor of Research in Population Health Sciences Population Health Sciences Weill Cornell Medical College   MedicalResearch.com:  What is the background for this study?    Response: The Omicron BA.1 and BA.2 variants resulted in a large wave of infections. The level of protection provided by prior infection or vaccination with Pfizer and Moderna mRNA vaccines or a combination of both against infection with Omicron BA.1 and BA.2 subvariants was unknown. (more…)
Author Interviews, Critical Care - Intensive Care - ICUs, NEJM, Vitamin C / 15.06.2022

MedicalResearch.com Interview with: François Lamontagne MD MSc (pharmacology) MSc (CEB) Professor of Medicine at the Université de Sherbrooke Endowed research chair on patient-centred research Dr. Neill Adhikari MDCM, M.Sc. Sunnybrook Research Institute and University of Toronto Toronto, Canada MedicalResearch.com:  What is the background for this study?  Response: The use of intravenous vitamin C for sepsis has been a hot topic for a few years. It was biologically plausible that vitamin C could reduce organ injury and death by scavenging reactive oxygen species and modulating the immune response to sepsis. It also seemed like an intervention that would be reasonably easy to administer globally should it prove beneficial. On the other hand, no intervention is benign and every aspect of health care should be rigorously studied. Regarding vitamin C, there were strongly held opinions in both camps and this motivated us to design and conduct the LOVIT trial. (more…)
Author Interviews, Breast Cancer, JAMA, Mammograms, Medical Imaging, UCSF / 15.06.2022

MedicalResearch.com Interview with: Karla Kerlikowske, MD. Professor, Departments of Medicine and Epidemiology/Biostatistics, Cancer Center Program Membership. Breast Oncology UCSF MedicalResearch.com:  What is the background for this study?  Response: Digital breast tomosynthesis (DBT) was developed with the expectation it would improve detection of breast cancer in women with dense breasts and decrease false-positive results. DBT is now available at most breast screening centers. (more…)
Author Interviews, Cancer Research, JAMA, Race/Ethnic Diversity / 10.06.2022

MedicalResearch.com Interview with: Marquita W. Lewis-Thames, PhD (she/her/Dr.) Assistant Professor, Department of Medical Social Science Center for Community Health, Member Researcher Assistant Directors of Community Outreach and Engagement, Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine, Northwestern University MedicalResearch.com:  What is the background for this study?  What are the main findings?  Response: Incidence, mortality, and survivorship provide a comprehensive description of cancer for a group of people. Differences in cancer incidence and mortality trends by rural-urban status and race and ethnicity are well documented, but urban-rural cancer survivorship trends by race and ethnicity are unknown. To this end, we examined almost 40 years of racial and ethnic differences by rural-urban status for 5-year survival of patients with lung, prostate, breast, and colorectal cancers. Using a nationwide epidemiological assessment of 1975-2011 data from the SEER database, we found that 5-year cancer-specific survival trends increased for all cancer types and race and ethnic groups, regardless of rural or urban status. Generally, rural, and non-Hispanic Black cancer patients had worse survival outcomes than others. (more…)
Author Interviews, Brigham & Women's - Harvard, Cost of Health Care, JAMA / 09.06.2022

MedicalResearch.com Interview with: Benjamin N. Rome MD Instructor, Harvard Medical School Internal Medicine Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women’s Hospital MedicalResearch.com:  What is the background for this study? What are the main findings?  Response: Manufacturers of brand-name drugs are granted periods, free from direct competition, during which they can set and raise prices as they choose. We found that the prices for newly marketed brand-name drugs increased by 20% per year from 2008 to 2021. In 2020 and 2021, nearly half of new drugs were launched at a price greater than $150,000 per year, compared with 9% of drugs in 2008-2013. These dramatic trends are only partly explained by changes in the types of drugs coming to market. (more…)
ASCO, Author Interviews, Breast Cancer, Cancer Research, Race/Ethnic Diversity / 09.06.2022

MedicalResearch.com Interview with: Sachi Singhal, MD Department of Medicine Crozer Chester Medical Center Upland, PA MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: This study focuses on analysing the National Inpatient Sample for patients with breast cancer, their breakdown by race, gender and US regions, and their mortality per sub-group. The main findings are that African Americans, especially AA women are at significantly increased odds of dying from metastatic breast cancer in the United States. (more…)
Author Interviews, Brain Injury, NEJM / 09.06.2022

MedicalResearch.com Interview with: Daniel Perl MD Uniformed Services University of the Health Sciences Professor of Pathology at USUHS and Director of the CNRM's Brain Tissue Repository Uniformed Services University of the Health Sciences Bethesda, Maryland MedicalResearch.com:  What is the background for this study?  Response: Chronic traumatic encephalopathy (CTE) is a brain disorder that is predominantly seen in individuals who have suffered from repeated impact head trauma, such as occurs in former boxers or American football players.  CTE has very specific alterations in the brain and can only be diagnosed at autopsy.  Some have claimed that, in addition to former contact sport participants, individuals who served in the military and were repeatedly exposed to blast (explosions) are also at increased risk for developing CTE.  However, this claim has been based on a rather small number of anecdotal cases.  The DoD/USU Brain Tissue Repository is the only facility in the world that is exclusively dedicated to the collection and study of donated brain specimens derived from deceased active duty and retired service members.  We used the resources of this facility to examine 225 consecutively collected brain specimens for the presence of CTE.  This would to provide a view of how common CTE was in this setting and, when diagnosed, was the disease correlated with prior blast exposure, participation in contact sports and other forms of head trauma, and with certain forms of symptomatology such as development of PTSD, alcohol/substance abuse, death by suicide, etc. (more…)
ASCO, Author Interviews, Cancer Research, COVID -19 Coronavirus, NYU / 08.06.2022

MedicalResearch.com Interview with: Katherine Garcia MD NYU Langone Health MedicalResearch.com:  What is the background for this study?  Response: Studies on cancer patients during the COVID-19 pandemic have shown a decrease in new diagnoses, delays in care, and a shift to later stage disease presentations. Considering that NY has been an epicenter for COVID-19 in the U.S., we investigated its impact on new cancer diagnoses at the two campuses of NYU’s Perlmutter Cancer Center and hypothesized that there would be a decrease in presentations during the peak outbreaks in NY. (more…)
Author Interviews, Diabetes, Kidney Disease / 08.06.2022

MedicalResearch.com Interview with: prof. dr. H.J. (Hiddo) Lambers Heerspink Clinical Pharmacologist Department Clinical Pharmacy and Pharmacology University Medical Center Groningen Groningen  MedicalResearch.com:  What is the background for this study?    Response: Tirzepatide is a novel GIP-GLP1 receptor agonist recently FDA approved for the treatment of type 2 diabetes. The SURPASS_4 trial demonstrated that in patients with type 2 diabetes at high cardiovascular risk tirzepatide compared to insulin glargine markedly reduces Hba1c and body weight. About 1 out of 3 patients with type 2 diabetes and CV disease has kidney disease and these patients are at high risk of kidney failure. The aim of this study was to assess whether tirzepatide could slow CKD progression in high risk individuals with type 2 diabetes participating in the SURPASS 4 trial.  (more…)
Addiction, Author Interviews, Opiods / 07.06.2022

MedicalResearch.com Interview with: Colleen G. Jordan, MBS Department of Medical Education Geisinger Commonwealth School of Medicine MedicalResearch.com: What is the background for this study? Response: Opioid addiction and misuse remain a prevalent issue in the United States (U.S.). There have been more than one-million drug overdoses in the U.S. since 1999 [1], largely driven by opioids, which exacerbate the strain on resources in hospitals, treatment centers, first responders, patients, and their families. The existing pharmacotherapies for opioid use disorder (OUD) are not working. Naloxone is a competitive mu opioid receptor antagonist used to reverse respiratory and CNS depression in those experiencing an opioid overdose but requires further dosing to prevent subsequent overdose. Naltrexone is a competitive mu opioid receptor antagonist, and has extended-release formulations intended to reduce relapse and promote adherence, yet patient noncompliance and retention continue to be limiting factors. Methadone is commonly used to treat opioid addiction as a replacement for illicit opiates but is itself an addictive substance which can result in overdoses [2] and can lead to withdrawal if not closely monitored by a licensed professional. Buprenorphine is currently used to treat opioid use disorder (OUD), and while it reduces illicit drug use, it is less effective than methadone for retaining patients in treatment. For these reasons, there is an urgent need for new opioid misuse interventions. The objectives of this study [3] were to understand the implications of OUD and overdose treatments and determine the strengths and shortcomings of current treatments in comparison with the novel drug candidate methocinnamox (MCAM). These were completed through an extensive literature review into the history of the opioid epidemic in the United States, opioid receptors in the brain, current pharmacological treatments, and the pharmacological properties of MCAM. (more…)
Author Interviews, COVID -19 Coronavirus, Mental Health Research, Rheumatology / 07.06.2022

MedicalResearch.com Interview with: Kelly Gavigan, MPH Director, Data Management and Analytics Global Healthy Living Foundation MedicalResearch.com:  What is the background for this study?  Response: COVID-19 is of particular concern for people living with autoimmune and rheumatic disease, not only because they have an increased risk of infection but also because of the heightened sense of isolation due to strict social distancing protocols that many patients continue to follow through today. As a result, we wanted to better understand if symptoms among the autoimmune and rheumatic disease patients in our ArthritisPower research registry were impacted throughout the COVID-19 pandemic. We previously conducted and reported on an analysis of patient reported outcome data from the ArthritisPower registry between the months of January 2020 to April 2021 at the American College of Rheumatology Convergence in 2021. We conducted a follow-up analysis between May and December 2021, which is our area of focus in this particular abstract. (more…)
Annals Internal Medicine, Author Interviews, Brigham & Women's - Harvard, Diabetes, Heart Disease / 07.06.2022

MedicalResearch.com Interview with: HoJin Shin, BPharm, PhD Postdoctoral Research Fellow Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston, Massachusetts MedicalResearch.com:  What is the background for this study?  Response: The public health burden of cardiovascular disease has been increasing in people with diabetes along with the burden of diabetes itself.
  •  Cardiovascular disease affects approximately one-third of the population with type 2 diabetes and accounts for     50%–80% of their mortality
  • 1 in 10 people in the US has diabetes
Since 2008, the US FDA has recommended post-approval cardiovascular outcome trials to ensure the safety of new glucose-lowering drugs responding to this growing burden of cardiovascular disease in type 2 diabetes and the potential increase in cardiovascular risk with certain existing glucose-lowering drugs (e.g., rosiglitazone). Notably, SGLT-2i have demonstrated superiority to placebo in reducing the risk of cardiovascular events, including hospitalization for heart failure. Consequently, beginning in 2018, clinical guidelines in the US have recommended SGLT-2i as a preferred second-line treatment for patients with type 2 diabetes and cardiovascular disease. As the paradigm of second-line pharmacological treatment for type 2 diabetes has shifted to include the management of cardiovascular risk in addition to glycemic control, this further raised the question of whether SGLT-2i should be advanced to first-line treatment. Since 2019, SGLT-2i have been recommended as a first-line agent for patients with type 2 diabetes and cardiovascular disease by the European guidelines (the European Society of Cardiology and the European Association for the Study of Diabetes). In the absence of head-to-head RCTs, non-randomized studies using real-world data could provide information on whether SGLT-2i may have greater cardiovascular benefits over metformin more timely than randomized clinical trials among both patients with and without existing CVD. Therefore, we evaluated the risk for cardiovascular events among adults with T2D who initiated treatment with first-line SGLT-2i versus metformin in clinical practice. (more…)
Nutrition, Vegetarians / 06.06.2022

Vegetarianism is one of the biggest dietary trends. Many people are switching to this lifestyle choice to better their health, reduce their carbon footprint, and do their part in animal welfare. What’s more, many people don’t commit fully; some choose to enjoy meat-free days during the week or month instead. Thus, going vegetarian is more flexible and easier than you might have previously believed. Naturally, there are many health benefits of eating less meat; here, they will be discussed. (more…)
Author Interviews, Gout, JAMA, Kidney Disease / 06.06.2022

MedicalResearch.com Interview with: Csaba P Kovesdy MD FASN Fred Hatch Professor of Medicine Director, Clinical Outcomes and Clinical Trials Program Division of Nephrology, University of Tennessee Health Science Center Nephrology Section Chief, Memphis VA Medical Center Memphis TN, 38163 MedicalResearch.com:  What is the background for this study?  What are the main findings?  Response: Hyperuricemia has unfavorable metabolic effects and has been associated with higher risk of progressive kidney disease and mortality. Despite this, earlier clinical trials have failed to prove a beneficial impact on kidney disease progression from uric acid lowering therapy in patients with preexisting CKD. The effect of uric acid lowering therapy on the development of new onset CKD in patients with normal kidney function has not been well studied. In our large observational study we did not find a beneficial association between newly initiated uric acid lowering therapy (the majority of which was in the form of allopurinol). On the contrary, uric acid lowering therapy was associated with a slightly higher risk of new onset low eGFR and new onset albuminuria, especially in patients with less elevated baseline serum acid levels. (more…)
Author Interviews, Cancer Research, Nature, Pancreatic, University of Michigan / 03.06.2022

MedicalResearch.com Interview with: Imad Shureiqi, MD, MS Professor, Division of Hematology and Oncology Department of Internal Medicine Rogel Cancer Center Ann Arbor, MI, 48109 MedicalResearch.com:  What is the background for this study?   Response: Pancreatic ductal adenocarcinoma is a highly lethal form of cancer with rising occurrence, and strategies to prevent and treat the disease are urgently needed. Most cases of pancreatic cancer arise from pre-cancerous lesions called pancreatic intraepithelial neoplasia (PanIN); about 55-80% of adults over forty are estimated to have these low-grade pre-cancerous silent pancreatic lesions. But critical factors that promote the progression of pancreatic pre-cancerous lesions to pancreatic cancer remain poorly defined, especially those easy to target. Findings from this publication indicate that people who have silent PanIN pre-cancerous lesions, even those that are low-grade, could increase their risk of PanIN progression into pancreatic cancer by consuming activators of a nuclear lipid receptor called peroxisome proliferator-activated receptor-delta (PPARδ). PPARδ activators can be natural substances, such certain fatty acids like palmitic and arachidonic acid in high-fat diets, or synthetic ones, like Cardarine (GW501516). (more…)